HighTide Therapeutics is a clinical-stage biopharmaceutical company based in Rockville, MD, led by CEO Liping Liu. The company discovers and develops novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. Its lead drug candidate, HTD1801, is a new molecular entity in clinical development for type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). The U.S. FDA has granted Fast Track designation to HTD1801 for NASH and PSC and Orphan Drug designation for PSC. In China, HTD1801 is included in the National Major New Drug Innovation Program. The company recently completed a $107M Series C/C+ financing to support its pipeline advancement. HighTide intends to use the proceeds to advance multiple global development programs, including mid- to late-stage clinical trials, and to support commercialization and business development activities.

Total raised

$107M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2023